HONG KONG – Japan's embattled conglomerate Toshiba Corp. has plans to sell off between half and all of the shares of its medical equipment subsidiary as it restructures its operations in the wake of a multi-billion dollar loss last year.
HONG KONG – Fear of biosimilars, drugs that once launched will potentially capture entire markets with their discounted prices, is not likely to be an issue in some of the poorer countries in Asia and Latin America, where even cheaper biosimilars are too expensive for the general public. With numerous patient access challenges, biosimilars have had a difficult time finding their footing in some of these markets.
HONG KONG – Fear of biosimilars, drugs that once launched will potentially capture entire markets with their discounted prices, is not likely to be an issue in some of the poorer countries in Asia and Latin America, where even cheaper biosimilars are too expensive for the general public. With numerous patient access challenges, biosimilars have had a difficult time finding their footing in some of these markets.
HONG KONG – The chill of a wide-ranging anti-corruption campaign in China that has led to some very high-profile arrests spread with news that Guo Guangchang, the chairman of Fosun International Ltd., may have been snared in a corruption investigation. Shares of its subsidiary, Fosun Pharmaceutical Group Co. Ltd. (HKEX:2196, SS:600196), plunged more than 12 percent Monday on the Hong Kong stock exchange and about 4 percent in Shanghai.
HONG KONG – The chill of a wide-ranging anti-corruption campaign in China that has led to some very high-profile arrests spread with news that Guo Guangchang, the chairman of Fosun International Ltd., may have been snared in a corruption investigation. Shares of its subsidiary, Fosun Pharmaceutical Group Co. Ltd. (HKEX:2196, SS:600196), plunged more than 12 percent Monday on the Hong Kong stock exchange and about 4 percent in Shanghai.
HONG KONG – Chinese biopharma company Huya Bioscience International LLC extended its global partnership and commercialization business model to South Korea, looking to replicate the success it has had taking promising compounds from one country – mostly China – and developing them elsewhere.
